Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 18/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17312488 | 1.00 | RIPK1 (0.41) | RIPK1ITGB3ITGA2BF2F10 | |
| SCHEMBL21111282 | 0.92 | RIPK1 (0.41) | RIPK1 | |
| SCHEMBL21111285 | 0.92 | RIPK1 (0.41) | RIPK1 | |
| SCHEMBL2236134 | 0.80 | RIPK1 (0.46) | RIPK1 | |
| SCHEMBL2236141 | 0.80 | RIPK1 (0.46) | RIPK1 | |
| SCHEMBL15956086 | 0.78 | RIPK1 (0.56) | RIPK1 | |
| SCHEMBL21111151 | 0.78 | USP30 (0.42) | RIPK1 | |
| SCHEMBL21111150 | 0.78 | USP30 (0.42) | RIPK1 | |
| SCHEMBL18409596 | 0.78 | RIPK1 (0.41) | RIPK1 | |
| SCHEMBL18409597 | 0.78 | RIPK1 (0.41) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556152-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-01-31 | — | — | US | disclosed |
| US-20150353533-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353533-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP3K3 | RIPK1 349/4885ITGB3 2383/4885ITGA2B 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.